NASDAQ: SVA - Sinovac Biotech Ltd.

Rentabilité sur six mois: 0%
Rendement en dividendes: 0%

Calendrier des promotions Sinovac Biotech Ltd.


À propos de l'entreprise Sinovac Biotech Ltd.

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps.

plus de détails
Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

IPO date 2003-11-03
ISIN AGP8696W1045
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт http://www.sinovacbio.com
Цена ао 6.47
Changement de prix par jour: 0% (6.47)
Changement de prix par semaine: 0% (6.47)
Changement de prix par mois: 0% (6.47)
Changement de prix sur 3 mois: 0% (6.47)
Changement de prix sur six mois: 0% (6.47)
Changement de prix par an: 0% (6.47)
Evolution du prix sur 3 ans: -22.05% (8.3)
Evolution du prix sur 5 ans: +0.6221% (6.43)
Evolution des prix depuis le début de l'année: 0% (6.47)

Sous-estimation

Nom Signification Grade
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
Total: 2.5

Efficacité

Nom Signification Grade
ROA, % 0 0
ROE, % 0 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0.6171

Devoir

Nom Signification Grade
Debt/EBITDA 0 10
Total: 10

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 82.15 9
Rentabilité Ebitda, % -624.78 0
Rentabilité EPS, % -121.87 0
Total: 1.8

Superviseur Titre d'emploi Paiement Année de naissance
Dr. Weidong Yin Chairman, CEO, Pres, MD, GM & Sec. 1965 (60 années)
Ms. Nan Wang CFO & VP of Bus. Devel. 1966 (59 années)
Mr. Qiang Gao VP & COO 1977 (48 années)
Mr. Ming Xia VP of Sales & Marketing 1974 (51 année)

Adresse: China, Beijing, No.39 SHANGDI West Road - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: http://www.sinovacbio.com